Glaxo Group Limited

Philip John Neale

Anthony James Taylor

The present invention relates to a pharmaceutical aerosol formulation which comprises particulate anhydrous beclomethasone dipropionate together with 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant, which formulation is free of surfactant. The formulation may also contain salbutamol and includes a canister suitable for delivery and a method of treating respiratory disorders administering the formulation by inhilation.

Aerosol formulation containing beclomethasone dipropionate and

This invention relates to novel aerosol formulations for administering drugs, in particular, for the administration of a beclomethasone ester, by inhalation. In particular, the invention provides novel aerosol formulations consisting essentially of (a) beclomethasone dipropionate in the form of a solvate with 1,1,1,2-tetrafluoroethane (CF.sub.3 CH.sub.2 F) and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellants, or (b) anhydrous beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant.

Aerosol formulations containing beclomethasone dipropionate-1, 1, 1,

Medicaments

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises: (a) beclomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns; (b) at least 0.015% by weight of the formulation of water in addition to the water of crystallization associated with the monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Growing community of inventors

Ware, United Kingdom

Philip John Neale